Rezolute, Inc. (RZLT) financial statements (2021 and earlier)
Company profile
Business Address |
201 REDWOOD SHORES PARKWAY, SUITE 315 REDWOOD CITY, CA 94065 |
State of Incorp. | DE |
Fiscal Year End | June 30 |
SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
12/31/2019 Q2 | 9/30/2019 Q1 | 6/30/2019 Q4 | 3/31/2019 Q3 | 12/31/2018 Q2 | 9/30/2018 Q1 | 6/30/2018 Q4 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 18 | 22 | 12 | 15 | 0 | 0 | 2 | ||
Cash and cash equivalents | 18 | 22 | 12 | 15 | 0 | 0 | 2 | ||
Receivables | 0 | ||||||||
Assets held-for-sale, not part of disposal group | 0 | ||||||||
Other current assets | 0 | 0 | 0 | 0 | |||||
Other undisclosed current assets | 2 | 4 | 1 | ||||||
Total current assets: | 20 | 26 | 12 | 15 | 0 | 1 | 2 | ||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 0 | 1 | ✕ | ✕ | ✕ | ||||
Property, plant and equipment | 0 | 0 | 0 | 0 | 0 | 0 | |||
Intangible assets, net (including goodwill) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Intangible assets, net (excluding goodwill) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Deposits noncurrent assets | 0 | 0 | |||||||
Deferred costs | 0 | 0 | |||||||
Other undisclosed noncurrent assets | 0 | 0 | 0 | 0 | |||||
Total noncurrent assets: | 1 | 1 | 0 | 0 | 0 | 0 | 0 | ||
TOTAL ASSETS: | 21 | 27 | 12 | 15 | 0 | 1 | 3 | ||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities, including: | 2 | 2 | 1 | 1 | 2 | 2 | 2 | ||
Accounts payable | 1 | 1 | |||||||
Employee-related liabilities | 1 | 0 | 1 | 1 | 1 | 1 | 1 | ||
Interest and dividends payable | 0 | 0 | 0 | 0 | |||||
Other undisclosed accounts payable and accrued liabilities | 0 | (0) | 1 | 1 | 1 | ||||
Debt | 0 | 0 | 0 | 0 | 0 | 4 | 3 | ||
Other liabilities | 1 | 0 | 0 | 0 | 0 | ||||
Other undisclosed current liabilities | 3 | 4 | 7 | 6 | 1 | 1 | 1 | ||
Total current liabilities: | 6 | 6 | 8 | 7 | 3 | 7 | 6 | ||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation | 0 | 0 | 5 | ||||||
Long-term debt, excluding current maturities | 5 | ||||||||
Operating lease, liability | 0 | 0 | ✕ | ✕ | ✕ | ||||
Liabilities, other than long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | |||
Other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |||
Other undisclosed noncurrent liabilities | 2 | 4 | 2 | 0 | 0 | ||||
Total noncurrent liabilities: | 0 | 0 | 2 | 4 | 7 | 0 | 0 | ||
Total liabilities: | 6 | 6 | 11 | 11 | 10 | 8 | 6 | ||
Stockholders' equity | |||||||||
Stockholders' equity attributable to parent | 15 | 21 | 2 | 5 | (10) | (6) | (4) | ||
Preferred stock | 31 | ||||||||
Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Additional paid in capital | 153 | 152 | 128 | 97 | 92 | 91 | 90 | ||
Accumulated deficit | (139) | (132) | (127) | (124) | (102) | (98) | (94) | ||
Total stockholders' equity: | 15 | 21 | 2 | 5 | (10) | (6) | (4) | ||
TOTAL LIABILITIES AND EQUITY: | 21 | 27 | 12 | 15 | 0 | 1 | 3 |
Income statement (P&L) ($ in millions)
12/31/2019 Q2 | 9/30/2019 Q1 | 6/30/2019 Q4 | 3/31/2019 Q3 | 12/31/2018 Q2 | 9/30/2018 Q1 | 6/30/2018 Q4 | ||
---|---|---|---|---|---|---|---|---|
Gross profit: | (0) | (0) | (1) | (0) | (0) | (0) | 0 | |
Operating expenses | (7) | (5) | (3) | (17) | (3) | (3) | (11) | |
Other undisclosed operating income (loss) | 0 | 0 | 1 | 0 | 0 | 0 | (0) | |
Operating loss: | (7) | (5) | (3) | (17) | (3) | (3) | (11) | |
Nonoperating income (expense) | 0 | 0 | (3) | (1) | (1) | (1) | ||
Investment income, nonoperating | (0) | 0 | 0 | 0 | 0 | |||
Gain on contract termination | 0 | 0 | ||||||
Interest and debt expense | (4) | (0) | (1) | (1) | (1) | |||
Net loss: | (7) | (5) | (7) | (20) | (5) | (4) | (13) | |
Other undisclosed net income attributable to parent | 0 | 4 | 0 | 1 | 1 | 1 | ||
Net loss attributable to parent: | (7) | (5) | (3) | (20) | (4) | (3) | (12) | |
Other undisclosed net loss available to common stockholders, basic | (2) | |||||||
Net loss available to common stockholders, diluted: | (7) | (5) | (3) | (22) | (4) | (3) | (12) |
Comprehensive Income ($ in millions)
12/31/2019 Q2 | 9/30/2019 Q1 | 6/30/2019 Q4 | 3/31/2019 Q3 | 12/31/2018 Q2 | 9/30/2018 Q1 | 6/30/2018 Q4 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (7) | (5) | (7) | (20) | (5) | (4) | (13) | |
Comprehensive loss: | (7) | (5) | (7) | (20) | (5) | (4) | (13) | |
Other undisclosed comprehensive loss, net of tax, attributable to parent | (2) | |||||||
Comprehensive loss, net of tax, attributable to parent: | (7) | (5) | (10) | (20) | (5) | (4) | (13) |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.